Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 13/20 | 0.55 |
| ▸ | SYK | P43405 | 2/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23029676 | 0.91 | ACP1 (0.51) | ACP1SYKSLC2A1 | |
| SCHEMBL29636807 | 0.87 | ACP1 (0.45) | ACP1SYKSLC2A1SMARCA2 | |
| SCHEMBL23029700 | 0.87 | SLC2A1 (0.60) | ACP1SLC2A1 | |
| Hydrochloric Acid SCHEMBL29636760 | 0.86 | SLC2A1 (0.59) | ACP1SLC2A1 | |
| SCHEMBL29636742 | 0.86 | ACP1 (0.50) | ACP1SLC2A1SMARCA2 | |
| SCHEMBL23015126 | 0.86 | ACP1 (0.50) | ACP1SLC2A1SMARCA2 | |
| Trifluoroacetic Acid SCHEMBL29636818 | 0.84 | ACP1 (0.47) | ACP1SLC2A1 | |
| SCHEMBL23029767 | 0.84 | SYK (0.46) | ACP1SYK | |
| SCHEMBL29636709 | 0.84 | SYK (0.46) | ACP1SYK | |
| SCHEMBL23029698 | 0.82 | SLC2A1 (0.48) | ACP1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 2022-12-08 | — | — | US | claimed |
| EP-4017492-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2022-06-29 | — | — | EP | claimed |
| CN-114667145-A | Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders | 拜尔哈文制药股份有限公司 | 2022-06-24 | — | — | CN | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 2022-12-08 | — | — | US | disclosed |
| CN-114667145-A | Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders | 拜尔哈文制药股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| WO-2021035101-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | TARDBP, TDP1, TDP2 | ACP1 1840/4885SYK 4777/4885SLC2A1 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.